<DOC>
	<DOCNO>NCT02472795</DOCNO>
	<brief_summary>International trial evaluate biological activity safety ACT-334441 lupus patient .</brief_summary>
	<brief_title>Clinical Study Investigate Biological Activity , Safety , Tolerability , Pharmacokinetics ACT-334441 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Male female subject age 18 65 year establish SLE . Subjects must active SLE , Systemic Lupus Erythematosus Disease Activity Index2000 ( SLEDAI2K ) score least 2 point musculoskeletal mucocutaneous manifestation history presence Screening positive antinuclear antibody ( ANA ) antidoublestranded DNA ( antidsDNA ) antibody . Enrolled subject must treat background SLE medication . Subjects significant medical condition therapy condition ( e.g. , cardiovascular , pulmonary , immunological , hepatic , ophthalmological , infection infection risk , history presence malignancy , history presence bone marrow solid organ transplantation ) lactate pregnant woman . Subjects severe SLE disease clinically relevant medical surgical condition , opinion investigator , would put subject risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
</DOC>